Wells Bio 웰스바이오 said Tuesday it has obtained domestic manufacturing and sale rights for “CareUS™ Strep A Plus,” a laryngopharyngitis diagnostic reagent kit, from the Ministry of Food and Drug Safety.
Strep A Plus is a highly sensitive diagnostic product launched in the advanced markets in Asia, U.S., and Europe. The kit uses the proteins of the Strep A bacteria, extracted from patient oral samples, to diagnose the patient.
It is designed to detect pathogens even in small quantities by maximizing the binding capacity of antigenic antibodies based on Ultra-HST, a diagnostic technology developed by their parent company, Access Bio 엑세스바이오. Also, compared to existing products the kit is more sensitive and only takes five minutes.
“Demand for laryngopharyngitis diagnostic kits has been steadily increasing due to the increased cases of sore throats for reasons such as seasonal change, fine dust, and yellow sand,” a company official said. “We will make efforts to minimize unnecessary prescriptions by treating patients with faster and more precise diagnosis with our highly sensitive diagnostic kit.”
Wells Bio will release the diagnostic kit in Korea this month and will focus on marketing with Access Bio to diversify their distribution network.
<© Korea Biomedical Review, All rights reserved.>